Pediatric endocrinology

Long-Term Treatment for Laron Syndrome with IGF-1 Injection over 22 Years in Saudi Arabia: A Cohort Study

Horm Res PaediatrPublished Retrospective cohort study

Main finding · Height velocityResult — go to the resultMean difference 3.1 cm/year

Authors' conclusion

IGF-1 therapy significantly enhanced linear growth in children with Laron syndrome and was generally well tolerated. Although many patients did not reach normal adult height, the growth achieved with IGF-1 treatment was markedly better than expected without therapy. This study underscores the effectiveness of IGF-1 in improving growth outcomes and highlights the need for continued longitudinal studies to optimize treatment strategies and manage potential complications.

Study context

Population
Patients with Laron syndrome (growth hormone (GH) insensitivity syndrome), 12 males and 16 females, treated 1998–2020 at KFSH & RC, Riyadh, Saudi Arabia; age >2 years, height standard deviation score (SDS) ≤−2.8, GH >2.5 ng/mL, IGF-1 <50 ng/mL, insensitivity to exogenous GH12 males · 16 females
Participants
28 patients
Exposure
IGF-1 therapy: on-treatment vs baseline
  • IGF-1n = 28
Outcome
Height velocity
Follow-up
First year
Methodological detailssingle-centre, long-term follow-up
  • Single-centre
  • Long-term follow-up

Main finding

As reported in the abstract

Mean difference

3.1 cm/year

P < 0.0001

Observational data: associations, not effects.

Further findings

OutcomeMean difference (cm/year)P value
Height velocity · second yearIGF-1 second year vs Baseline · HV 5 cm/year1.6P = 0.0015

Long-term height velocity · 10 years

Sustained height velocity (HV) improvements vs baseline, largest gains in the initial 5 years

Weight SDS

Weight SDSs also showed significant improvement

Growth by age at start and treatment duration

Age at start did not notably affect growth outcomes; longer treatment associated with greater growth

GHR genetic variants

Ten disease-causing GHR variants identified
24 of the 28 patients

Original publication

Long-Term Treatment for Laron Syndrome with IGF-1 Injection over 22 Years in Saudi Arabia: A Cohort Study. Horm Res Paediatr. Published 10 December 2024. doi:10.1159/000543047

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.